BeOne Medicines Q2 Earnings Call Highlights
MarketBeat
BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets.
Chief Executive Officer John Oyler said t
NASDAQ:ONC